Recombinant Human ANGPTL8/Betatrophin His-tag Protein, CF

When Recombinant Human Angiopoietin-like Protein 3/ANGPTL3 (Catalog # 3829-AN) is immobilized at 1 µg/mL (100 µL/well), Recombinant HumanANGPTL8/Betatrophin (Catalog # 10159-AN) binds with an ED50 of 0.15‑1.2 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ANGPTL8/Betatrophin His-tag Protein, CF Summary

• Additional Information: Mucin Stalk Chimera
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Angiopoietin-like Protein 3/ANGPTL3 (Catalog # 3829-AN) is immobilized at 1 μg/mL (100 μL/well), the concentration of Recombinant Human Angiopoietin-like Protein 8/Betatrophin that produces 50% of the optimal binding response is 0.15‑1.2 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Angiopoietin-like Protein 8/Betatrophin protein
  

  Human Angiopoietin-like Protein 8/Betatrophin (Ala22-Ala198) Accession # Q6UXH0	Human Fractalkine mucin-like stalk (Phe103-Thr338) Accession # P78423	6-His tag
  N-terminus		C-terminus

• Accession #: Q6UXH0 (Angiopoietin-like Protein 8/Betatrophin) &
• N-terminal Sequence: Ala22
• Protein/Peptide Type: Recombinant Proteins
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 45 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-93 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS, NaCl and CHAPS with Trehalose.
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ANGPTL8/Betatrophin His-tag Protein, CF

• Angiopoietin like Protein 8
• Angiopoietin-like Protein 8
• ANGPTL8
• Betatrophin
• C19orf80
• chromosome 19 open reading frame 80
• Gm6484
• hepatocellular carcinoma-associated gene TD26
• hepatocellular carcinoma-associated protein TD26
• Lipasin
• PRO1185
• PVPA599
• RIFL
• TD26
• UNQ599

Background

Betatrophin (also called ANGPTL8, lipasin and RIPL), a novel secretory protein from liver and fatty tissues, is believed to be involved in lipid and glucose metabolism. It is most homologous to ANGPTL3 but lacks the fibrinogen-like domain of ANGPTL3 and other ANGPTL family members (1). Human Betatrophin is 183 amino acids (aa) in length and shares 72% aa identity with mouse Betatrophin. Betatrophin is expressed in the liver, white adipose, and brown adipose tissues. It is a recently identified hormone which has been associated with two functionally important processes in the development of type 2 diabetes and obesity, insulin resistance as well as being a crucial modulator in lipid metabolism through regulation of serum triglyceride levels (2, 3). Betatrophin can form a complex with the N-terminal of ANGPTL3, and this complex is necessary for inhibition of lipoprotein lipase (LPL) activity and triglyceride modulation (4). Elevated levels of circulating betatrophin in the blood may be associated with gestational diabetes mellitus (GDM) and polycystic ovary syndrome (PCOS) (5, 6). Increased levels of Betatrophin in plasma and adipose tissue may also be associated with hypertension, coronary artery disease (CAD), and peripheral artery disease (PAD) (7, 8). The role of Betatrophin in inducing pancreatic beta-cell proliferation is controversial, as it did not control beta-cell expansion in the mouse model (9, 10). In addition to the lipid and glucose metabolism, ANGPTL8 has been reported to be involved in many other disorders such as non-alcoholic fatty liver disease and renal dysfunction (11).

1. Quagliarini, F. et al. (2012) PNAS 109:19751.
2. Abu-Farha M. et al. (2017) Diabetes Metab Res Rev. 33:e2919.
3. Zhang R. et al. (2012) Biochem Biophys Res Commun. 424:786
4. Chi, X. et al. (2017) Molecular Metabolism 6:1137.
5. Kong F.J. et al. (2017) PLoS One. 12:e0169941.
6. Varikasuvu S.R. et al. (2019) Gynecol Endocrinol. 35:190
7. Abu-Farha M. et al. (2018) Lipids Health Dis. 17:35
8. Niki H. et al. (2019) J Atheroscler Thromb. 26:573.
9. Abu-Farha M. et al. (2016) J Diabetes Res. 2016:4860595.
10. Cox A.R. et al. PLoS One (2016) 11:e0159276.
11. Luo, M. et al. (2018) Front Endocrino 9:169.

Publications for Angiopoietin-like protein 8/Betatrophin (10159-AN)(1)

Publication using 10159-AN

• Kraaijenhof, JM;Tromp, TR;Nurmohamed, NS;Reeskamp, LF;Langenkamp, M;Levels, JHM;Boekholdt, SM;Wareham, NJ;Hoekstra, M;Stroes, ESG;Hovingh, GK;Grefhorst, A; ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity Journal of the American Heart Association 2023-10-27 [PMID: 37889183]

Bioinformatics

• Uniprot:
  • Q6UXH0 (Angiopoietin-like Protein 8/Betatrophin) &()